Business Context and Reporting Period
Company: Greenwich LifeSciences, Inc. (GLSI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2024
Business Overview: A clinical-stage biopharmaceutical company developing GLSI-100, an immunotherapy to prevent breast cancer recurrence. The company is currently conducting the Phase III Flamingo-01 clinical trial. It has not generated any revenue to date and relies on capital raises to fund operations.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2024 | Nine Months Ended Sept 30, 2024 | Balance Sheet (Sept 30, 2024) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(2,668,713) | $(7,748,590) | N/A |
| Loss Per Share (Basic/Diluted) | $(0.20) | $(0.60) | N/A |
| Operating Expenses | $2,729,051 | $7,927,656 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $5,822,367 |
| Total Assets | N/A | N/A | $5,825,049 |
| Total Liabilities | N/A | N/A | $842,384 |
| Stockholders' Equity | N/A | N/A | $4,982,665 |
Cash Flow (Nine Months Ended Sept 30, 2024):
- Net cash used in operating activities: $(5,414,337)
- Net cash provided by financing activities: $4,247,280
- Net decrease in cash: $(1,167,057)
Material Changes vs. Prior Period
- Revenue: Remained at $0, consistent with the prior year period.
- Net Loss: Increased to $(7.75) million for the nine months ended Sept 30, 2024, compared to $(6.15) million in the same period in 2023. The increase is primarily attributed to higher clinical expenses.
- Operating Expenses:
- R&D: Increased 27% to $6.79 million (nine months) due to increased clinical trial costs.
- G&A: Increased 1% to $1.13 million (nine months).
- Liquidity: Cash balances decreased from $6.99 million (Dec 31, 2023) to $5.82 million (Sept 30, 2024).
- Liabilities: Accounts payable and accrued interest increased significantly from $256,317 to $774,759.
Guidance, Outlook, Risks, and Unusual Items
- Capital Raises:
- Issued 121,663 shares via ATM program (Jan–Sept 2024) for net proceeds of $1.75 million.
- Completed a private placement on June 13, 2024, selling 174,825 shares to the CEO for net proceeds of $2.50 million.
- On October 7, 2024, entered a new ATM agreement with H.C. Wainwright & Co. to sell up to $100 million of common stock.
- Going Concern: The filing includes a "Going Concern" warning. The company has incurred net losses since inception and has negative operating cash flows. Continued operations depend on obtaining additional capital.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2024, due to material weaknesses including inadequate segregation of duties and insufficient written policies.
- Outlook: The company expects to continue incurring significant expenses and operating losses as it expands the Flamingo-01 trial globally and prepares for commercialization.
Investor Verification Checklist
- Cash Runway: Verify if the current cash balance of ~$5.8 million is sufficient to fund the expanded Phase III trial through the next 12 months without further dilution.
- Internal Control Remediation: Review the specific plan management is developing to address the material weaknesses in internal controls over financial reporting.
- Dilution Risk: Monitor the utilization of the new $100 million ATM facility and the impact of potential future equity raises on share count.
- Clinical Trial Progress: Confirm the status of the Flamingo-01 trial expansion to 150 global sites and any interim data releases.
- Related Party Transactions: Note the $2.5 million private placement to the CEO and the accrued unreimbursed expenses from management ($67,625).